1Depatment of Pharmacology and Therapeutics, College of Medicine, Univerisity of Kufa, Iraq
2Department of Dermatology, Hammurabi College of Medeicine, University of Babylon, Iraq
*Corresponding author: Adhwaa Mohsen AL-Shimary, Depatment of Pharmacology and therapeutics, College of medicine, University of Kufa, Iraq
Online published on 2 February, 2019.
To evaluate the effect of simvastatin as an adjuvant with topical steroid on disease severity on patients with chronic plaque psoriasis. In a double blind study, 50 patients with plaque psoriasis have been randomly classifed in two group, for each group 25 patients. Group one received placebo plus topical steroid (Betamethasone dipropionate 0.5 mg/g and salicylic acid 30 mg/g) for 8 weeks and group two received simvastatin tab 40 mg once daily plus topical steroid for 8 weeks. PASI score was measured before and after treatment. Psoriasis area and severity index reduced signifcantly in both groups, but the decline of psoriasis severity in simvastatin group was more signifcant (P< 0.001). In addition signifcant decrease of IL-17 and TNF-a (P< 0.001).
Simvastatin, psoriasis, Topical steroid
